Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR10624 in Healthy, Obese, and Hypertriglyceridemia Subjects
NCT05378893Phase 1Completed
- Sponsor
- Doer Bio
- Start
- Jun 2022
- Primary completion
- Oct 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DR10624 in obesity and hypertriglyceridemia (6 arms), sponsored by Doer Bio. Primary endpoint: Safety and Tolerability at Day 106. Started Jun 2022; status: completed.
02
Drugs
DR10624
03
Conditions
obesityhypertriglyceridemia
Beyond the preview
Go deeper on NCT05378893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05378893.